Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,362 across all filing types
Latest filing 2021-09-09 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司股东集中竞价减持股份结果公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from 亚宝药业集团股份有限公司 regarding the results of a concentrated share reduction by a major shareholder, 山西亚宝投资集团有限公司. It details the number of shares held before and after the reduction, the reduction plan, the actual shares reduced, and confirms that the reduction plan was implemented as disclosed. The document is short (1433 characters) and focuses on shareholding changes by a major shareholder, specifically the reduction of shares through centralized bidding. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. It is not an annual report, earnings release, or other financial report, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is MRQ with high confidence.
2021-09-09 Chinese
亚宝药业集团股份有限公司关于5%以上股东减持比例达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder who holds more than 5% of the company's shares reducing their stake by more than 1%. It details the shareholder's name, the number of shares reduced, the percentage change, and confirms that this does not affect control of the company or trigger a tender offer. The document is short (1558 characters) and focuses on shareholding changes by a major shareholder. This matches the definition of a Major Shareholding Notification (MRQ). There is no indication that this is a full financial report, management change, or other types of filings. Therefore, the correct classification is MRQ.
2021-08-27 Chinese
亚宝药业集团股份有限公司关于全资子公司取得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its wholly-owned subsidiary obtaining a drug registration certificate from the National Medical Products Administration. It details the drug's specifications, approval, and related information. The document is short (1118 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed management discussion. There is no financial data, no mention of annual or quarterly results, no governance changes, no voting results, or other report types. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories.
2021-08-20 Chinese
亚宝药业集团股份有限公司第八届董事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from 亚宝药业集团股份有限公司, dated August 21, 2021. It states that the board reviewed and approved the company's 2021 half-year report (interim report) and amendments to the related party transaction management system. The document itself does not contain the full interim report or detailed financial data but announces the approval of the interim report and related resolutions. The document length is short (464 characters), and it serves as an official announcement of board decisions rather than the full interim report. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal announcement of board resolutions and report approval, not the report itself.
2021-08-20 Chinese
亚宝药业集团股份有限公司2021年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2021 年半年度报告" which translates to "2021 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company overview, business segments, and operational details for the first half of 2021. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial analysis. The content matches the characteristics of an Interim / Quarterly Report (IR) rather than a brief announcement or a full annual report (10-K). The document is not a mere announcement or certification, but a comprehensive report for a period shorter than a full fiscal year, consistent with the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-20 Chinese
亚宝药业集团股份有限公司关联交易管理制度
Governance Information Classification · 95% confidence The document is titled '关联交易管理制度' which translates to 'Related Party Transaction Management System' and contains detailed rules and procedures regarding related party transactions, including definitions, decision-making authority, pricing, disclosure, and exemptions. It is a governance-related document outlining internal policies and compliance with regulatory requirements for related party transactions. There is no indication that this is an annual report, audit report, earnings release, or any other financial statement. It is not a meeting presentation or voting result announcement. The content fits best under governance information as it details internal rules and governance practices related to related party transactions.
2021-08-20 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.